• In February 2026, Aurinia Pharmaceuticals reported fourth-quarter 2025 revenue of US$77.11 million and full-year revenue of US$283.06 million, alongside a very large increase in net income and earnings per share versus 2024.
• On the same day, the company issued 2026 guidance calling for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million, signaling management’s confidence in its operating momentum and product demand.
• We’ll now examine how Aurinia’s stronger 2025 profitability and higher 2026 revenue outlook might reshape its existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Aurinia Pharmaceuticals Investment Narrative Recap

To own Aurinia Pharmaceuticals, you need to believe LUPKYNIS can support a durable, profitable franchise while the pipeline gradually reduces single‑drug dependency. The sharp improvement in 2025 earnings and management’s 2026 revenue outlook strengthens the near term catalyst around execution on LUPKYNIS demand. However, it does not remove the key risk that any setback for this one product, or pressure on its pricing and access, could quickly change the company’s financial profile.

The most relevant recent announcement is Aurinia’s 2026 guidance for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million. This targets double digit growth over 2025 and directly ties into the short term catalyst of continued LUPKYNIS uptake. At the same time, it sits against ongoing concerns about drug pricing pressure and regulatory scrutiny that could affect future reimbursement and margins.

Yet even with stronger 2025 profits and higher 2026 revenue guidance, investors should be aware that concentrated reliance on LUPKYNIS still leaves Aurinia heavily exposed to...

Aurinia Pharmaceuticals' narrative projects $386.4 million revenue and $141.3 million earnings by 2028. This requires 14.1% yearly revenue growth and about an $80.7 million earnings increase from $60.6 million today.

Uncover how Aurinia Pharmaceuticals' forecasts yield a $17.00 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were assuming revenue of about US$344 million and earnings near US$86 million by 2028, which is a far more cautious view than the consensus. When you compare that to the latest results and guidance, you can see how sharply opinions differ and why it is worth understanding how these more pessimistic expectations might change after such a strong earnings report.

Explore 6 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth 22% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 50 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.